Within the FDA, blood apparently is not thicker than water. An unusually public tiff has arisen over the use of angiotensin receptor blockers, or ARBs, which millions of Americans use to prevent heart attack, stroke and heart failure. Some dissenting doctors within the FDA feel that not enough research has gone into monitoring some of the unintended consequences of the drugs, namely, high cancer rates.
NOT FOR REPRINT
Dispute flares inside FDA over safety of popular blood drugs
By
Staff Writer
May 31, 2013 at 01:13 PM
Share & Print
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
